Market Overview

Pluristem's PLX Cells Demonstrate Efficacy in Preliminary Animal Experiment for Graft vs Host Disease

Pluristem Therapeutics (NASDAQ: PSTI) announced today that the company's PLacental eXpanded (PLX) cells demonstrated efficacy in a preliminary animal experiment for the treatment of Graft versus Host Disease (GvHD) following bone marrow transplantation (BMT). The results showed that PLX cells, regardless of their administration route, intravenous (IV) or intramuscular (IM), demonstrated a statistically significant improvement (p < 0.05) in the GvHD score. Following interest from leading medical institutions, Pluristem is investigating a potential cooperation to bring this indication to a clinical trial.

GvHD may occur after BMT when patients receive bone marrow tissue or cells from a donor and these newly transplanted cells regard the recipient's body as foreign, attacking the recipient's body. The global incidence of acute GvHD ranges from 26% to 34% in recipients of fully matched sibling donor grafts, to 42% to 52% in recipients of matched unrelated donor grafts.

The animal study was conducted in the laboratories of the Department of Bone Marrow Transplantation, Hadassah Medical Center, the Hebrew University, Jerusalem.

In the study, mice underwent total

See full press release

Posted-In: News Guidance Contracts Management Global

 

Most Popular

Related Articles (PSTI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free